Gulf International Bank UK Ltd increased its position in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 2.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 14,201 shares of the medical equipment provider’s stock after purchasing an additional 400 shares during the period. Gulf International Bank UK Ltd’s holdings in ABIOMED were worth $6,386,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. NEXT Financial Group Inc bought a new stake in shares of ABIOMED during the third quarter valued at approximately $115,000. TRUE Private Wealth Advisors bought a new stake in shares of ABIOMED during the third quarter valued at approximately $162,000. OLD Mutual Customised Solutions Proprietary Ltd. bought a new stake in shares of ABIOMED during the second quarter valued at approximately $164,000. Rampart Investment Management Company LLC bought a new stake in shares of ABIOMED during the second quarter valued at approximately $175,000. Finally, NewSquare Capital LLC bought a new stake in shares of ABIOMED during the second quarter valued at approximately $186,000. Institutional investors and hedge funds own 87.14% of the company’s stock.
Shares of ABMD stock opened at $405.17 on Friday. The firm has a market capitalization of $18.56 billion, a P/E ratio of 133.37, a P/E/G ratio of 3.37 and a beta of 0.35. ABIOMED, Inc. has a one year low of $186.72 and a one year high of $459.75.
ABIOMED (NASDAQ:ABMD) last announced its quarterly earnings results on Thursday, November 1st. The medical equipment provider reported $1.09 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.36. The business had revenue of $181.78 million for the quarter, compared to analyst estimates of $175.41 million. ABIOMED had a return on equity of 20.09% and a net margin of 27.60%. ABIOMED’s quarterly revenue was up 36.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.54 EPS. Equities analysts forecast that ABIOMED, Inc. will post 3.57 earnings per share for the current year.
A number of analysts have recently issued reports on ABMD shares. BidaskClub cut ABIOMED from a “buy” rating to a “hold” rating in a research report on Tuesday, July 31st. Zacks Investment Research cut ABIOMED from a “buy” rating to a “hold” rating in a research report on Tuesday, July 31st. ValuEngine cut ABIOMED from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 18th. Morgan Stanley boosted their price objective on ABIOMED from $370.00 to $396.00 and gave the company an “equal weight” rating in a research report on Thursday, October 11th. Finally, BTIG Research raised ABIOMED from a “neutral” rating to a “buy” rating and set a $450.00 price target on the stock in a research note on Friday, November 2nd. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. ABIOMED has a consensus rating of “Buy” and an average target price of $402.78.
In other ABIOMED news, VP Michael G. Howley sold 10,000 shares of the business’s stock in a transaction on Tuesday, September 25th. The stock was sold at an average price of $432.50, for a total value of $4,325,000.00. Following the transaction, the vice president now owns 48,954 shares of the company’s stock, valued at $21,172,605. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Andrew J. Greenfield sold 4,440 shares of the business’s stock in a transaction on Wednesday, August 29th. The stock was sold at an average price of $395.00, for a total value of $1,753,800.00. The disclosure for this sale can be found here. 3.50% of the stock is owned by insiders.
ILLEGAL ACTIVITY NOTICE: This piece was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/11/10/gulf-international-bank-uk-ltd-grows-stake-in-abiomed-inc-abmd.html.
ABIOMED Company Profile
ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.
See Also: Inflation
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.